Royce & Associates LP Has $9.08 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Royce & Associates LP raised its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 46.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 362,873 shares of the company’s stock after acquiring an additional 115,486 shares during the quarter. Royce & Associates LP’s holdings in Centessa Pharmaceuticals were worth $9,075,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. PSP Research LLC acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $547,000. GSA Capital Partners LLP increased its stake in Centessa Pharmaceuticals by 76.5% in the 4th quarter. GSA Capital Partners LLP now owns 33,104 shares of the company’s stock valued at $828,000 after buying an additional 14,343 shares during the last quarter. DNB Asset Management AS increased its stake in shares of Centessa Pharmaceuticals by 41.8% during the 4th quarter. DNB Asset Management AS now owns 12,746 shares of the company’s stock worth $319,000 after purchasing an additional 3,758 shares during the last quarter. Sigma Planning Corp bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $225,000. Finally, B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $961,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Up 0.1%

Shares of CNTA opened at $39.81 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $10.95 and a 52 week high of $40.26. The firm has a market cap of $5.94 billion, a P/E ratio of -22.24 and a beta of 1.13. The firm’s 50-day simple moving average is $37.52 and its 200 day simple moving average is $29.87. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CNTA. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday, March 31st. B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Lifesci Capital cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their target price for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Finally, Guggenheim cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Hold” and an average price target of $41.33.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at $1,735,805.25. This represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 309,112 shares of company stock worth $8,424,535. 4.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.